gutflix
GI learning, personalised

Summary

Introduction: Pancreatic and small bowel neuroendocrine tumours

Hana Algül

Postgraduate Teaching Programme Barcelona 2026 | Presentation

Small Intestine & Nutrition | Pancreas | Digestive Oncology

October 17, 2026

This introductory session addresses the heterogeneity of digestive neuroendocrine tumours, emphasizing that pancreatic and small bowel NETs share a common classification but differ substantially in biology, genetics, hormonal syndromes, and treatment evidence.

KEY POINTS

- The speaker stated that pancreatic and small bowel neuroendocrine tumours share neuroendocrine differentiation and WHO classification grading but have different biology, genetics, grade spectrum, and spread patterns.
- Trial results cannot be transferred automatically between pancreatic and small bowel sites due to their different treatment evidence.
- Management approaches vary widely, ranging from surveillance to multimodal therapies including surgery, liver-directed therapies, somatostatin analogues, PRRT, targeted therapies, and chemotherapy.
- Hormonal syndrome management is sometimes required to control symptoms in these patients.
- The session continues with a pathology expert discussing classification systems for these heterogeneous tumours.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/c2e6af60-d14f-11f1-997c-daaa6dbee0a2

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.